Document is current
Any future updates will be listed below
-
Authors
Xu, Zhi Ming
Zwyer, Michaela
Hiza, Hellen
Schmidiger, Sarah
Sasamalo, Mohamed
Reinhard, Miriam
Doetsch, Anna
Borrell, Sonia
Naret, Olivier
Rüeger, Sina
Lawless, Dylan
Tang, Simon
Isihaka, Faima
Temba, Hosiana
Maroa, Thomas
Naftari, Rastard
Beisel, Christian
Hella, Jerry
Reither, Klaus
Brites, Daniela
Portevin, Damien
Gagneux, Sebastien
Fellay, Jacques
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (CRSII5-177163, CRSII5-177163)
European Research Council (883582)
- License Information
-
More Information
Article History
Received: 11 January 2025
Accepted: 13 May 2025
First Online: 2 June 2025
Declarations
:
: Ethical approval for the TB-DAR cohort has been obtained from the Ethikkommission Nordwest- und Zentralschweiz (EKNZ UBE-15/42), the Ifakara Health Institute—Institutional Review Board Board (IHI/IRB/EXT/No: 24–2020) and the National Institute for Medical Research in Tanzania—Medical Research Coordinating Committee (NIMR/HQ/R.8c/Vol.I/1622). A written informed consent has been obtained from every patient who has been recruited into the TB-DAR cohort. This study was conducted in compliance with the Declaration of Helsinki.
: Not applicable.
: O.N. is now an employee of SUN bioscience SA. S.R. is now an employee of Novartis AG. All other authors declare that they have no competing interests.
